Genotypic resistance testing in HIV-infected pregnant women in an urban setting

International Journal of STD and AIDS

Volumn 15, Issue 6, 2004, Pages 384-387

  Shah, S S ^a,b   Crane, M ^a   Monaghan, K ^a   McGowan, J P ^a,b  

^a BRONX LEBANON HOSPITAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretroviral resistance; Genotype; Human immunodeficiency virus; Pregnancy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES; URBAN AREA; VIRUS MUTATION;

ADULT; ANTI-RETROVIRAL AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 2942744608     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646204774195236     Document Type: Article

References (10)

1. CDC, US Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR 2002;51(RR-18)1-38
2. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Biern Community Program for Clinical Research on AIDS. AIDS 2000;14:F83-93
3. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579-88
4. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-26
5. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15:309-20
6. British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIV Medicine 2001;2:314-34
7. D'Aquila RT, Schapiro JM, Brun-Vezinet, et al. Drug Resistance Mutations in HIV-1. Updated October, 2002. Available at: [www.iasusa.org/ resistance_mutations/resistance.pdf]. Accessed March 2, 2003
8. DeJose MI, Ramos JT, Alvarez S, Jiminez JL, Munoz-Fernandez MA. Vertical transmission of HIV-1 varients resistant to reverse transcriptase and protease inhibitors. Arch Intern Med 2001;161:2738-9
9. Parker M, Wade N, Gallagher BK, et al. Prevalence of genotypic drug resistance in HIV-infected newborns in New York State [abstract 800-W]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002
10. Little SJ, Holte S, Routy J-P, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94